Increased C-reactive protein and decreased Interleukin-2 content in serum from obese individuals with or without insulin resistance: Associations with leukocyte count and insulin and adiponectin content

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 10, Issue 1, 2016, Pages S34-S41

  Vargas, Renata ^a   Ryder, Elena ^a   Diez Ewald, María ^a   Mosquera, Jesús ^a   Durán, Anyelo ^a   Valero, Nereida ^a   Pedreañez, Adriana ^a   Peña, Caterina ^a   Fernández, Erika ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Cytokines; Inflammation; Insulin; Obesity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; HEMOGLOBIN A1C;

ADULT; ANTHROPOMETRY; ARTERIAL PRESSURE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; INTRAPERITONEAL FAT; LEAN BODY WEIGHT; LEUKOCYTE COUNT; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; COMPLICATION; METABOLISM; MIDDLE AGED; YOUNG ADULT; ANTHROPOMETRIC PARAMETERS;

ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-2; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OBESITY; THINNESS; YOUNG ADULT;

EID: 84951819518     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2015.09.007     Document Type: Article

References (59)

1. [1] Pecht, T., Gutman-Tirosh, A., Bashan, N., Rudich, A., Peripheral blood leukocyte subclasses as potential biomarkers of adipose tissue inflammation and obesity subphenotypes in humans. Obes Rev 15 (2014), 322–337, 10.1111/obr.12133.
2. [2] Carvalheira, J.B., Qiu, Y., Chawla, A., Blood spotlight on leukocytes and obesity. Blood 122 (2013), 3263–3267, 10.1182/blood-2013-04-459446.
3. [3] de Heredia, F.P., Gómez-Martínez, S., Marcos, A., Obesity, inflammation and the immune system. Proc Nutr Soc 71 (2014), 332–338, 10.1017/S0029665112000092.
4. [4] Castell, J.V., Gomez-Lechon, M.J., David, M., Fabra, R., Trullenque, R., Heinrich, P.C., Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12 (1990), 1179–1186.
5. [5] Heinrich, P.C., Castell, J.V., Andus, T., Interleukin-6 and the acute phase response. Biochem J 265 (1990), 621–636.
6. [6] Verma, S., Wang, C.H., Li, S.H., Dumont, A.S., Fedak, P.W., Badiwala, M.V., et al. A self-fulfilling prophecy: C reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002), 913–919.
7. [7] Montero, I., Orbe, J., Varo, N., Beloqui, O., Monreal, J.I., Rodríguez, J.A., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 47 (2006), 1369–1378.
8. [8] Hattori, Y., Matsumura, M., Kasai, K., Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 58 (2003), 186–195.
9. [9] Smigiel, K.S., Srivastava, S., Stolley, J.M., Campbell, D.J., Regulatory, T., cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev 259 (2014), 40–59, 10.1111/imr.12170.
10. [10] Pierson, W., Cauwe, B., Policheni, A., Schlenner, S.M., Franckaert, D., Berges, J., et al. Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3(+) regulatory T cells. Nat Immunol 14 (2013), 959–965, 10.1038/ni.2649.
11. [11] Deng, G., Podack, E.R., Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci U S A 90 (1993), 2189–2193.
12. [12] Chen, C., Rowell, E.A., Thomas, R.M., Hancock, W.W., Wells, A.D., Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 281 (2006), 36828–36834.
13. [13] Williams, L.M., Rudensky, A.Y., Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8 (2007), 277–284.
14. [14] Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446 (2007), 685–689.
15. [15] Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126 (2006), 375–387.
16. [16] Arnaiz, P., Acevedo, M., Barja, S., Aglony, M., Guzmán, B., Cassis, B., et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int J Cardiol 138 (2008), 138–144.
17. [17] Dandona, P., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., Assian, E., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 86 (2001), 3257–3265.
18. [18] Aljada, A., Ghanim, H., Mohanty, P., Kapur, N., Dandona, P., Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87 (2002), 1419–1422.
19. [19] Dandona, P., Aljada, A., Dhindsa, S., Garg, R., Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone 4 (2003), S13–S20.
20. [20] Ryder, E., Mijac, V., Fernández, E., Palazzi, N., Morales, M.C., Connell, L., et al. Esteatosis hepática, grasa visceral y alteraciones metabólicas en individuos con sobrepeso/obesidad aparentemente sanos. Invest Clin 55 (2014), 3–14.
21. [21] Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
22. [22] Buccini, G., Wolftbal, D.L., Valores de corte para indices de insulinoresistencia, insulinosensibilidad e insulinosecrecion derivados de la formula HOMA y del programa HOMAZ. Interpretación de los datos. Rev Argent Endocrinol Metab 45 (2008), 3–21.
23. [23] Garmedia, M.L., Lera, L., Sanchez, H., Vauy, R., Albala, C., Homeostasis model assessment (HOMA) values in Chilean elderly subjects. Rev Med Chile 137 (2009), 1409–1416 pii:S0034-98872009001100001.
24. [24] Hanley, A.J., Retnakaran, R., Qi, Y., Gerstein, H.C., Perkins, B., Raboud, J., et al. Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. Clin Endocrinol Metab 94 (2009), 3824–3832, 10.1210/jc.2009-0719.
25. [25] Gkrania-Klotsas, E., Ye, Z., Cooper, A.J., Sharp, S.J., Luben, R., Biggs, M.L., et al. Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PLoS ONE, 5, 2010, e13405, 10.1371/journal.pone.0013405.
26. [26] Lee, C.T., Harris, S.B., Retnakaran, R., Gerstein, H.C., Perkins, B.A., Zinman, B., et al. White blood cell subtypes, insulin resistance and β-cell dysfunction in high-risk individuals – the PROMISE cohort. Clin Endocrinol (Oxf) 81 (2013), 536–541, 10.1111/cen.12390.
27. [27] Ryder, E., Diez-Ewald, M., Mosquera, J., Fernández, E., Pedreañez, A., Vargas, R., et al. Association of obesity with leukocyte count in obese individuals without metabolic syndrome. Diabetes Metab Syndr 8 (2014), 197–204, 10.1016/j.dsx.2014.09.002.
28. [28] Lorenzo, C., Hanley, A.J., Haffner, S.M., Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetología 57 (2014), 83–92, 10.1007/s00125-013-3080-0.
29. [29] Beauloye, V., Zech, F., Tran, H.T., Clapuyt, P., Maes, M., Brichard, S.M., Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metabol 92 (2007), 3025–3032.
30. [30] Arnaiz, P., Pino, F., Marín, A., Barja, S., Aglony, M., Cassis, B., et al. Subclinical atherosclerosis: classic and emerging cardiovascular risk factors in Chilean obese children. Rev Chil Pediatr 78 (2007), 135–142.
31. [31] Kapiotis, S., Holzer, G., Schaller, G., Haumer, M., Widhalm, H., Weghuber, D., et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol 26 (2006), 2541–2546.
32. [32] Roh, E.J., Lim, J.W., Ko, K.O., Cheon, E.J., A useful predictor of early atherosclerosis in obese children: serum high-sensitivity C-reactive protein. J Korean Med Sci 22 (2007), 192–197.
33. [33] Ryder, E., Pedreañez, A., Vargas, R., Peña, C., Fernandez, E., Diez-Ewald, M., et al. Increased proinflammatory markers and lipoperoxidation in obese individuals: inicial inflammatory events?. Diabetes Metab Syndr, 2014, 10.1016/j.dsx.2014.04.022 pii:S1871-4021(14)00034-4.
34. [34] Schmidt, F.M., Weschenfelder, J., Sander, C., Minkwitz, J., Thormann, J., Chittka, T., et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLOS ONE, 10, 2015, e0121971, 10.1371/journal. pone.0121971.
35. [35] Lucas, R., Parikh, S.J., Sridhar, S., Guo, D.H., Bhagatwala, J., Dong, Y., et al. Cytokine profiling of young overweight and obese female African American adults with prediabetes. Cytokine 64 (2013), 310–315, 10.1016/j.cyto.2013.05.025.
36. [36] Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., Akhlaghi, S., et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Sci World J, 2014, 2014, 898361, 10.1155/2014/898361.
37. [37] Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 (1993), 253–261.
38. [38] Willerford, D.M., Chen, J., Ferry, J.A., Davidson, L., Ma, A., Alt, F.W., Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3 (1995), 521–530.
39. [39] Kosmaczewska, A., Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci 15 (2014), 18574–18592, 10.3390/ijms151018574.
40. [40] Reaven, G.M., The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 25 (2005), 391–406.
41. [41] Osborn, O., Olefsky, J.M., The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18 (2012), 363–374, 10.1038/nm.2627.
42. [42] Romeo, G.R., Lee, J., Shoelson, S.E., Metabolic syndrome, insulin resistance, and roles of inflammation – mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 32 (2012), 1771–1776, 10.1161/ATVBAHA.111.241869.
43. [43] Watanabe, Y., Nagai, Y., Takatsu, K., Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients 5 (2013), 3757–3778, 10.3390/nu5093757.
44. [44] Cornier, M.A., Dabelea, D., Hernandez, T.L., Lindstrom, R.C., Steig, A.J., Stob, N.R., et al. The metabolic syndrome. Endocr Rev 29 (2008), 777–822, 10.1210/er.2008-0024.
45. [45] Annadurai, T., Thomas, P.A., Geraldine, P., Ameliorative effect of naringenin on hyperglycemia-mediated inflammation in hepatic and pancreatic tissues of Wistar rats with streptozotocin-nicotinamide-induced experimental diabetes mellitus. Free Radic Res 47 (2013), 793–803, 10.3109/10715762.2013.823643.
46. [46] Pessin, J.E., Saltiel, A.R., Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106 (2000), 165–169.
47. [47] Alkhouri, N., Morris-Stiff, G., Campbell, C., Lopez, R., Tamimi, T.A., Yerian, L., et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 32 (2012), 297–302, 10.1111/j.1478-3231.2011.02639.x.
48. [48] Yue, C.C., Muller-Greven, J., Dailey, P., Lozanski, G., Anderson, V., Macintyre, S., Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J Biol Chem 271 (1996), 2245–2250.
49. [49] Carolan, E., Hogan, A.E., Corrigan, M., Gaotswe, G., O'Connell, J., Foley, N., et al. The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression. J Clin Endocrinol Metab 99 (2014), E474–E478.
50. [50] Petersen, A.M., Pedersen, B.K., The antiinflammatory effect of exercise. J Appl Physiol 98 (1985), 1154–1162.
51. [51] Roth, C.L., Kratz, M., Ralston, M.M., Reinehr, T., Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism 60 (2011), 445–452, 10.1016/j.metabol.2010.03.023.
52. [52] Shi, C., Zhu, L., Chen, X., Gu, N., Chen, L., Zhu, L., et al. IL-6 and TNF-α Induced obesity-related inflammatory response through transcriptional regulation of mir-146b. J Interferon Cytokine Res 34 (2014), 342–348, 10.1089/jir.2013.0078.
53. [53] Genest, J., C-reactive protein: risk factor, biomarker and/or therapeutic target?. Can J Cardiol 26 (2010), 41a–44a.
54. [54] Choi, J., Joseph, L., Pilote, L., Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14 (2013), 232–244, 10.1111/obr.12003.
55. [55] Farooq, W., Farwa1, U., Khan, F.R., The metabolic syndrome and inflammation: role of insulin resistance and increased adiposity. Oman Med J 30 (2015), 100–103.
56. [56] Todendi, P.F., Klinger, E.I., Ferreira, M.B., Reuter, C.P., Burgos, M.S., Possuelo, L.G., et al. VALIM5 association of IL-6 and CRP gene polymorphisms with obesity and metabolic disorders in children and adolescents. An Acad Bras Cienc 87 (2015), 915–924, 10.1590/0001-3765201520140364.
57. [57] D'Alessandris, C., Lauro, R., Presta, I., Sesti, G., C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 50 (2007), 840–849.
58. [58] Meijer, K., de Vries, M., Al-Lahham, S., Bruinenberg, M., Weening, D., Dijkstra, M., et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS ONE, 6, 2011, e17154, 10.1371/journal.pone.0017154.
59. [59] Nazarov, P.G., Reaction of C-reactive protein with lnterleukin-2 receptor-chain. Bull Exp Biol Med 125 (1998), 582–584.